Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection

Clinical and Experimental Immunology

Volumn 176, Issue 1, 2014, Pages 102-111

  Deng, Y R ^a,b   Yoshida, K ^e   Jin, Q L ^d   Murata, M ^e   Yamaguchi, T ^e   Tsuneyama, K ^f   Moritoki, Y ^g   Niu, J Q ^d   Matsuzaki, K ^e   Lian, Z X ^a,c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HBV; PSmadC; PSmadL; TGF

Indexed keywords

LAMIVUDINE; SMAD3 PROTEIN; TELBIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; YOUNG ADULT;

HBV; PSMADC; PSMADL; TGF-Β;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; THYMIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895547979     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12259     Document Type: Article

References (45)

1. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7:425-436.
2. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
3. Omata M, Yoshida H. Prevention and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S111-114.
4. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
5. Jiang ZS, Jhunjhunwala S, Liu JF etal. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012; 22:593-601.
6. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351:317-320.
7. Yu DY, Moon HB, Son JK etal. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999; 31:123-132.
8. Koike K, Moriya K, Iino S etal. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19:810-819.
9. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
10. Marcellin P, Chang TT, Lim SG etal. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
11. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
12. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
13. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, de Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994; 38:2180-2182.
14. Dienstag JL, Goldin RD, Heathcote EJ etal. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
15. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
16. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
17. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465-471.
18. Wrana JL. Regulation of Smad activity. Cell 2000; 100:189-192.
19. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700.
20. Feng XH, Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21:659-693.
21. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19:71-88.
22. Furukawa F, Matsuzaki K, Mori S etal. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38:879-889.
23. Mori S, Matsuzaki K, Yoshida K etal. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004; 23:7416-7429.
24. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-231.
25. Matsuzaki K, Murata M, Yoshida K etal. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46:48-57.
26. Murata M, Matsuzaki K, Yoshida K etal. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009; 49:1203-1217.
27. Nagata H, Hatano E, Tada M etal. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology 2009; 49:1944-1953.
28. Yoshida K, Matsuzaki K, Mori S etal. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005; 166:1029-1039.
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
30. Sekimoto G, Matsuzaki K, Yoshida K etal. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 2007; 67:5090-5096.
31. Liang X, Bi S, Yang W etal. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27:6550-6557.
32. Weissberg JI, Andres LL, Smith CI etal. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101:613-616.
33. Realdi G, Fattovich G, Hadziyannis S etal. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21:656-666.
34. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630-1635.
35. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
36. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17:103-106.
37. Yamaguchi T, Matsuzaki K, Inokuchi R etal. Phosphorylated Smad2 and Smad3 signaling: shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res 2013; 43:1327-1342.
38. Suzuki Y, Kumada H, Ikeda K etal. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30:743-748.
39. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13:123-135.
40. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
41. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007; 31:1243-1248.
42. Rabe C, Pilz T, Klostermann C etal. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7:208-215.
43. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011; 13:842-848.
44. Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15:261-279, vii-x.
45. Yun C, Cho H, Kim SJ etal. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004; 2:159-169.